Gary M. Tse

HER2-low metastatic breast cancers: clinic-pathological characteristics, metastatic sites, and survival impact on biomarker discordance

Abstract Trastuzumab Deruxtecan has shown promising results in patients with HER2-low and -ultralow (UL) metastatic breast cancers, attracting extensive research on these tumors. While most studies focus on primary tumors, there is limited data on metastatic disease. Here, we aim...